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Patient education and self-management programmes have proved effective in many studies with short follow-up 
periods. We studied the 3-year cost-effectiveness of an intensive programme of patient education and supervision for 
self-management. 
The study consisted of 162 consecutive newly diagnosed asthmatics who were randomized either into an 
intervention group (IG) receiving intensive patient education and supervision for self-management at an outpatient 
clinic during the first year, or a control group (CG) receiving conventional education at the baseline visits only. Both 
groups had 2 additional years of follow-up. Lung functions and health-related quality of life (HRQOL) were 
measured. Extra direct and indirect costs were recorded. 
At 3 years the differences in forced expiratory volume in 1 s (FEV,) and in peak expiratory flow (PEF) were 
significantly better in the IG being in (% predicted) respectively 53 (95% CI 06-10.0) and 4.4 (95% CI O.l-8.7), 
(PcO.05). The airway responsiveness (PD,,) did not differ significantly, but the improvement from baseline to 
3 years was significantly greater in the IG, being 0.40 dose steps (95% CI 0.05-0.75) (PcO.05). HRQOL scores did 
not differ significantly. The risk for sickness day was less in the IG with a RR of 0.6 (95% CI 0.50-0.69) (P=O.OOO) 
and among patients who used the PEF meter. The compliance was similar in both groups when measured by the 
PEF-based self-management. There was no statistically significant difference in costs, although there was a 
consistent tendency for lower costs in the intensive programme. 
The intensive programme was more effective in terms of FEV,, PEF and improvement in PD,, and equally 
effective in terms of other lung functions and HRQOL, but there was no clear difference in the costs. 
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Introduction 
National and international asthma management guidelines 
usually include principles of medical treatment and 
additionally emphasize the importance of patient education 
and self-management (l-3). These activities are thought to 
contain the total social costs of asthma as the number of 
asthmatics increases (1). However, economic evaluations of 
patient education and self-management among asthmatics 
show conflicting results. Most studies have been performed 
in moderate and severe asthmatics with l-year follow-up 
and selected outcomes and costs (4-9). In one study the 
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follow-up time was 3 years, but only costs due to hospital- 
ization and lost productivity were included (10). Our earlier 
study dealt with new asthmatics, but the follow-up time 
was only 1 year (11). There are no controlled long-term 
economic studies of the impact of intensive patient 
education in new asthmatics. 
The aim of this study was to compare the long-term 
cost-effectiveness of an intensive programme of patient 
education and supervision for self-management in newly 
diagnosed asthmatics during the first treatment year with 
that of a conventional programme. 
Materials and Methods 
STUDY DESIGN 
The study was carried out at South Karelia Central 
Hospital in Finland. Between September 1991 and 
February 1993, 162 consecutive new asthmatics aged 18-76 
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TABLE 1. Baseline characteristics of the patients (standard 
deviations in parentheses) 
Intervention Control 
(n=80) (n=82) 
Sex (M/F) 
Mean age in years (range) 
Atopy* 
Current smokers 
FVC, % of predicted 
FEV,, % predicted 
FEV,IFVC 
PEF 
15D score 
SGRQ total score 
Treatment 
Inhaled corticosteroid 
Nedocromil 
25155 35147 
43.1 (18-76) 44.2 (19-76) 
52 39 
19 16 
95.1 (12.5) 92.5 (14.8) 
86.1 (14.0) 82.8 (14.8) 
90.0 (10.0) 89.1 (9.7) 
84.3 (11.4) 83.4 (13.5) 
0.89 (0.10) 0.89 (0.10) 
27.0 (14.6) 27.7 (15.6) 
75 
5 
77 
5 
*At least one positive skin prick test reaction to common 
allergens. 
years and diagnosed according to the American Thoracic 
Society criteria were included in the study (12). They 
showed a reversible airways obstruction with an increase of 
at least 15% in the forced expiratory volume in 1 set (FEV,) 
or in peak expiratory flow (PEF) in response to broncho- 
dilators. None of them had used anti-inflammatory asthma 
medication before. One month later they visited the attend- 
ing chest physician for conventional guidance in treatment 
and self-management and were informed about the study. 
Patients were then randomized into an intervention 
group (IG) or a control group (CG) using a computerized 
list with consecutive numbers. The duty nurse then made 
the next appointments according to the study plan. The IG 
visited the specialist clinic every third month during the first 
year, alternately to the respiratory nurse or attending chest 
physician for patient education and supervision for self- 
management. The CG had patient education and guidance 
for self-management only at their baseline and randomiz- 
ation visits. The next planned visit was 11 months after 
randomization. After 1 year primary health care assumed 
responsibility for all patients. The patients were invited to 
the 3-year control at the hospital by letter. 
The IG consisted of 80 patients and the CG of 82 
patients. The patients’ baseline characteristics are given in 
Table 1. The study plan was approved by the Hospital 
Ethical Committee and informed consent was obtained 
from all patients. 
TREATMENT 
All patients followed a routine treatment program consist- 
ing of higher doses of inhaled corticosteroid or nedocromil 
during the first 2 months, which they then decreased 
according to PEF monitoring. Most patients took inhaled 
corticosteroid from the outset, while 10 patients started 
with nedocromil. The patients had to buy their own drugs. 
The medication was prescribed for 1 year and the pharma- 
cies supplied the medication for 3 months’ use at a time. 
The mean prescribed maintenance doses were 1.01 mg 
beclomethasone, 0.97 mg budesonide and 11 mg nedocro- 
mil in the IG, and I.03 mg beclomethasone, 0.97 mg 
budesonide and 10 mg nedocromil in the CG. The inhaled 
bronchodilating medication was used as needed. Cortico- 
steroid tablets were not prescribed in advance because 
that was not the routine practice in our clinic for new 
asthmatics. The patients were advised to contact their 
health centre if they had problems with treatment. Com- 
pliance was monitored on the basis of verbal information 
given by the patient. At the l-year visit the attending chest 
physician checked the adequacy of maintenance asthma 
medication and made adjustments if needed. 
THE EDUCATION PROGRAMME 
The conventional patient education programme covered the 
use of inhaled drugs, PEF monitoring and principles of 
treatment. At the randomization visit, the patients were 
shown a video-tape on asthma and instructed in self- 
management by the chest physician, who explained the 
principles and importance of self-management and wrote 
the personal instructions to the diary according to the plan 
to be described below. This programme was administered 
by two respiratory nurses specially trained for that purpose. 
This basic education package was given to both patient 
groups during visits for diagnosis and randomization. 
The one-to-one education for the IG patients continued 
during their visits to the clinic every third month, including 
the repetition of self-management instructions, principles of 
asthma treatment and use of drugs. The nurse used an 
average of 1.5 h per patient for education and arranging 
appointments. Between the 6- and 9-month visits, all IG 
patients participated in a 2-h education programme given 
by a physiotherapist and two nurses, one of whom special- 
ized in social affairs and the other in rehabilitation. The 
course was attended by two or three asthmatic patients at a 
time. 
At the l-year follow-up visit, the attending chest 
physician repeated the principles of the self-management 
programme to all patients and revised the self-management 
plan as deemed necessary. 
SELF-MANAGEMENT PLAN 
A peak-flow meter and a diary were given to both groups 
for the first year. Patients were asked to monitor their PEF 
values whenever symptoms appeared, and for at least 2 
weeks every third month, and to record the values in the 
diary. This plan is similar to that later adopted in the 
Finnish asthma programme (1). 
The instructions in the diary were as follows: 
l If the PEF value falls below 80-85% of the predicted or 
of your individual optimal value, the inhaled cortico- 
steroid or nedocromil dosage should be doubled until the 
PEF level is normal and stabilized. 
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l If the PEF value falls below 70%, double the dosage and 
contact your doctor. 
l If the PEF value falls below SO%, go to an emergency 
department. 
l Use your inhaled bronchodilating drug whenever you 
have symptoms. 
Both groups recorded the use of extra health-care 
services, extra medication and sickness days in the diary. 
After the first year the patients were asked to buy their 
own PEF meter and use it whenever symptoms appeared, 
and to check their PEF at least once a month in the 
morning. They were also asked to monitor PEF for 2 weeks 
before the 3-year visit. The patient was defined as a 
complier if he or she had used the PEF meter at least once 
a month, always during the symptoms and at least 6 days 
before the follow-up visit. Advice for symptom-based 
follow-up was also given, although the attending chest 
physician encouraged all patients to buy a PEF meter (13). 
The chest physician advised doubling the inhaled anti- 
inflammatory drug and regularly using bronchodilator if 
the patient noticed symptoms such as early morning cough- 
ing and night-time wheezing, decreased tolerance to 
exercise and/or an increased need for bronchodilatator. 
The patient was advised to contact his or her general 
practitioner or to go to the emergency department if the 
increased medication did not give any relief and broncho- 
dilator was needed more than six times a day. 
OUTCOME MEASUREMENTS 
Clinical measurements at baseline and at 12 and 36 months 
were performed at least 12 h after the latest use of 
bronchodilating drugs. Two flow volume spirometers, 
Medikro 101 and 901 (Medikro Ltd, Kuopio, Finland), 
were calibrated daily and the correlation of the two differ- 
ent spirometers was tested for agreement with a healthy 
person before being used to measure lung function. PEF 
was measured with Wright’s PEF meter (Clement Clarke 
International Ltd., Harlow, Essex, U.K.) during the visits. 
The normal Finnish spirometric and Nunn’s PEF values 
were used, adjusted for age, gender and height (14,15). The 
results are given as percentages of normal values. Airway 
responsiveness was measured by the provocative dose of 
histamine required to cause a 15% fall in FEV, (PD,,) (16). 
Changes in airway responsiveness were expressed as the 
mean change in dose steps of PD,,, which were: step 0, 
PD,, co.11 mg; step 1, PDi, O.ll-0.4mg; step 2, PD,, 
0.41-1.6 mg; and step 3, PD,, 21.6 mg. At baseline the air- 
way responsiveness and spirometric values were measured 
before any use of inhaled anti-inflammatory drugs. 
Health-related quality of life (HRQOL) was measured 
by the generic 15D and disease specific St George’s 
Respiratory Questionnaire (SGRQ). The dimensions of 
the 1.5D are moving, seeing, hearing, breathing, sleeping, 
eating, communicating, eliminating, working, social partici- 
pation, mental functioning, pain/ache, depression, distress 
and perceived health. The score is on a O-l scale (1 =full 
HRQOL, O=death) (17). Among the Finnish population 
the average 15D score for an individual is 0.96 at 3544 
years and 0.92 at 65-74 years (18). 
The SGRQ has 76 items divided into three domains, 
symptoms, activity and impact on daily life, from which 
the total score (O-100 scale) is calculated (19,20). Zero is 
the best possible score. The patients completed the 
questionnaires during their visits. 
COSTS 
The costing of visits to the outpatient clinic, inpatient days, 
and emergency visits was based on the all-inclusive (labour, 
capital, maintenance etc.) unit costs prevailing in South 
Karelia Central Hospital in 1993. Visits to primary health 
centres as well as the return transportation costs were 
valued at the mean of such costs in Finland. The cost of 
time used by the nurses and physiotherapist was calculated 
from their gross salary of&l 3 h - ‘, including social security 
contributions. Any extra drugs used (oral corticosteroids 
and antibiotics) were valued at average retail prices. Also 
the use of regular asthma drugs, valued at the retail price, in 
the 2-latter follow-up years (years 2 and 3) was included, 
but this information was not available from the database of 
the Social Insurance Institution for the first treatment year. 
The total patient time taken by the intervention visits and 
extra health-care visits plus all sickness day was recorded 
for the calculation of indirect costs. The total working time 
thus lost was valued at the rate of the average daily gross 
wage in Finland, including social security contributions 
(&89 day - ‘). 
The costs of diagnosis, the visit for randomization and 
the follow-up visits at 12 and 36 months were not included, 
since they were the same in both groups and thus do not 
affect the relative cost of the alternatives. 
The cost-effectiveness of the intervention compared with 
the conventional programme was examined in the light of 
incremental cost-effectiveness ratios with all outcome vari- 
ables. The net monetary benefit of the intervention was 
calculated by subtracting from the intervention cost the 
saving due to the intervention (cost of the conventional 
programme minus the extra costs of the intervention 
programme). 
The main results are presented undiscounted. As a form 
of sensitivity analysis the difference between the groups in 
the total costs is also reported as discounted at 3 and 6%. 
STATISTICAL ANALYSIS 
Outcome variables are reported as mean values with a 95% 
confidence interval. Differences between the groups in all 
outcome variables at baseline and at 3 years were tested by 
using the Student’s t-test. Differences in outcome variables 
between baseline and 3 years within the groups were tested 
with the paired t-test. Differences between distributions 
were tested by the chi-squared test. A P-value ~0.05 was 
considered significant. 
Results 
At baseline there was no significant difference between the 
groups in any variable. Three IG patients did not attend 
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TABLE 2. The mean values of lung functions (as % predicted) and dose steps of histamine PD,, at baseline and at 3-year 
follow-up in both groups (95% CI in parentheses) 
Intervention group Control group 
Baseline 3 years Baseline 3 years 
Difference between 
Difference between groups intervention and control 
groups in change 
Baseline 3 years from baseline to 3 years 
FVC 95.1 94.8 92.5 91.4 
(92.2, 98.1) (91.4, 98.3) (89.2, 95.8) (88.5, 94.4) ( - 1286 7.0) (- 1y 7.9) 
FEV, 86.1 89.2* 82.8 83.9 5.3t 
(82.8, 89.4) (85.6, 92.8) (79.5, 86.1) (80.7, 87.0) (- 134: 7.9) (0.6, 10.0) 
FEV% 90.0 93.8*** 89.1 92.0** 
(87.7, 92.3) (91.3, 96.3) (86.7, 91.2) (89.7, 94.3) (- 2!2: 4.1) (- I!; 5.2) 
PEF 84.3 91+6*** 83.4 87.2** 
(- 3!19 5.0) 
4.4t 
(81.7, 87.0) (88.7, 94.6) (80.4, 86.4) (84.1, 90.4) 
- 0104 
(0.1, 8.7) 
PD,, as 0.54 1.57*** 0.58 1.26*** 0.30 
dose steps (0.36, 0.72) (1.31, 1.82) (0.40, 0.76) (1.03, 1.49) ( - 0.29, 0.21) ( - 0.04, 0.64) 
- 0.35 
( - 4.3, 3.6) 
- 1.67 
(- 5.7, 2.3) 
- 0.86 
(- 3.5, 1.8) 
- 3.24 
(26.8, 0.4) 
0.40t 
(0.05, 0.75) 
Significance of the differences between baseline and 3 years: ***P<O.OOl, **P<O.Ol, *P<O.O5 (paired sample t-test). 
Significance of the differences between groups: tPcO.05 (Student’s t-test). 
the control visits during the first year, later three moved 
away and two were unwilling to attend as they had become 
symptomless. This left 72 patients for evaluation at 3 years. 
Two CG patients dropped out during the first year: one 
died in a traffic accident and one moved away. Two other 
patients failed to attend at 3 years, leaving 78 patients to be 
evaluated in the CG. 
Among the IG patients there was a significant improve- 
ment from baseline to 3 years in all clinical and other 
outcome variables except FVC. The same also applied to 
the CG, except that there was no significant change in 
FEV,. At 3 years the difference in % predicted between 
groups in FEV, was 5.3 (95% CI O&10.0) and in PEF it 
was 4.4 (95% CI 0.1-8.7); both were significantly better 
(PcO.05) in the IG (Table 2). There was no difference in the 
improvement of lung function between current smokers and 
non-smokers. Most of the smokers (n=22) were under 
40 years old. 
Airway responsiveness was not tested at baseline in four 
IG patients deemed too symptomatic to be included, and 
at 3 years in two patients who had a common cold. In the 
CG, eight patients were not tested at baseline, as four 
were pregnant and four were too symptomatic, and at 3 
years six patients were not tested: one was pregnant, two 
had acute exacerbation and three had respiratory infec- 
tion. There was no difference between the groups in the 
airway responsiveness at 3 years (Table 2), but the 
improvement in dose steps from baseline to 3 years was 
significantly greater in the IG, the difference between the 
groups being 0.40 dose steps (95% CI 0.05-0.75) (PcO.05) 
. At baseline one patient and at 3 years 20 IG patients 
had the normal level of PD,, 1.6 mg or over and, respect- 
ively, in the CG two patients at baseline and seven 
patients at 3 years. At baseline there was no difference 
between the groups but at 3 years the difference in 
distribution was significant (P=O.O04). 
Airway responsiveness deteriorated by one dose step in 
two patients in the IG and in six patients in the CG during 
the 3-year follow-up. 
The mean doses of inhaled anti-inflammatory medica- 
tion used did not differ significantly between the groups at 
baseline or at 3 years. Apart from six patients switching 
from nedocromil to inhaled corticosteroid, there were no 
other significant changes in the mean maintenance 
dosages used according to the information given by the 
patients and the compliance was considered similar in 
both groups. 
HRQOL scores improved significantly in both groups 
from baseline to 3 years, but there was no significant 
difference between the groups (Table 3). Neither of the 
HRQOL scores reached the normal level (18,19). 
There was a significant difference only in a couple of cost 
items from 1 to 3 years. The average cost of primary care 
services was &5 (o-45) in the IG and &12 (O-134) in the CG 
(95% CI - 13.4 - 1.3) (PcO.05) and of extra courses of 
antibiotics &l (O-28) and f4 (O-69) respectively (95% CI 
- 5.8- - 0.3) (PcO.05). The average cost of regular asthma 
drugs in years 2-3 was &476 in the IG and f595 in the CG 
(P=O.18). The average total 3-year extra costs (without 
regular asthma drugs) were &464 in the IG, of which &247 
was for the intervention, compared to &477 in the CG 
(Table 4), suggesting a mean net saving of &12 with the 
intervention (95% CI - 286-262; not significant). When 
discounted at 3 and 6% the saving was &ll and &8, 
respectively. With cost of regular asthma drugs included the 
mean net saving rose to &131; the difference was not 
statistically significant. 
The IG patients experienced 104 sickness days and the 
CG patients 273 days during the 3 years, mostly during 
the first treatment year, at respectively 64 and 193 days. The 
risk ratio for sickness day was significantly less in the IG 
with a risk ratio (RR) of 0.6 (95% CI 0.5-0.7) (P=O.OOO). 
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TABLE 3. The mean HRQOL scores at baseline and at 3 years in the intervention and control groups (95% CI in parentheses) 
Intervention group Control group 
Baseline 3 years Baseline 3 years 
Difference between groups 
Baseline 3 years 
Difference between 
intervention and control 
groups in change 
from baseline to 3 years 
15D 0.89 0.92** 0.89 0.92** 0.01 0.00 
(087, 0.92) (0.91, 0.94) (086, 0.91) (0.90, 0.94) ( - 0.03, 0.04) ( - 0.02, 0.03) 
SGRQ 27.0 15.5*** 27.7 16.8*** - 0.70 - 1.31 
total (23.6, 30.5) (12.5, 18.4) (24.2, 31.3) (13.5, 20.0) (- 5.61, 4.21) (- 5.67, 3.05) 
SGRQ 58.2 34.5*** 57.5 35.0*** 0.69 - 0.47 
symptom (54.0, 62.3) (29.3, 39.7) (52.9, 62.3) (30.0, 40.0) (- 5.47, 6.84) (- 7.59, 6.65) 
SGRQ 28.1 17.0*** 28.1 17.9*** - 0.03 - 0.96 
activity (23.5, 32.6) (12.9, 21.1) (23.0, 33.2) (13.7, 22.2) ( - 6.85, 6.79) (- 6.85, 4.93) 
SGRQ 16.3 8.5*** 17.9 10.2*** - 1.53 - 1.78 
impact (12.8, 19.9) (6.1, 10.9) (14.5, 21.2) (7.4, 13.1) (- 6.32, 3.27) (- 5.47, 1.91) 
- 0.01 
( - 0.03, 0.02) 
1.44 
(- 2.68, 5.55) 
2.36 
(- 5.32, 10.04) 
1.41 
( - 4.63, 7.45) 
1.15 
(- 2.71, 5.01) 
Significance of the differences between baseline and 3 years: ***P<O.OOl, **P<O.Ol, *P<O.O5 (paired sample t-tests). 
The sickness days did not correlate with either lung 
functions or airways hyperresponsiveness in either 
group. 
In the IG, those patients who were defined to be compli- 
ers (n =20) had 3 1 sickness days and non-compliers 73 days, 
with RR of 0.6 (95% CI 0.4-0.8) (P=O.OOO). In the CG, 
compliers (n= 18) had 68 sickness days and non-compliers 
had 205 days, with an RR of 0.5 (95% CI 04-0.6) 
(P=O.OOO). The using of PEF-based self-management was 
not dependent on gender, smoking habit, atopy, lung 
function, airway responsiveness nor the amount of medica- 
tion used. However, the compliance was dependent on the 
age of the patients in the both groups. In the IG the mean 
age of compliers was 50 years and in the CG 51 years. 
Respectively the mean age of non-compliers was in the IG 
40 years and in the CG 42 years. The differences were 
significant in both groups (P=O.O2). 
Thirty-one patients in the IG and 40 in the CG used only 
symptom-based follow-up without having bought a PEF 
meter. Twenty-one patients in both group had a meter 
without using it. 
TABLE 4. The mean extra direct, indirect and total costs of 
asthma treatment (&) in the groups from baseline to 3 years. 
The costs of visits for diagnosis, randomization and l-year 
follow-up, and of regular drug therapy, are not included 
Intervention group* Control group 
mean (range) mean (range) 
Direct costs 226 (140-1751) 160 (O-1634) 
Indirect costs 238 (10771630) 316 (O-801 1) 
Total costs 464 (247-2939) 476 (O-8 157) 
*Includes intervention costs: direct &140, indirect &107; 
f sterling=approx. 8 FIM. 
Discussion 
The findings indicate that at 3-year follow-up the intensive 
patient education in self-management plus supervision 
during the first year was significantly more effective in terms 
of FEV,, PEF and improvement in airway responsiveness 
than the conventional programme. In the IG the mean 
FEV, improved from 85.7 to 89.2% of the predicted value. 
However, at 1 year FEV, was 92.3% of predicted. The 
decline of FEV, after the supervision year may indicate that 
better results in clinical measures were due to regular 
supervision rather than better self-management. The 
improvement was greater among new asthmatics than in 
the study by Lahdensuo et al. on 115 asthmatics. These 
patients had a similar self-management programme but 
they had trial medication, so the difference cannot be 
explained in terms of compliance (21). 
Among current smokers it is difficult to make a distinc- 
tion between asthma and other chronic obstructive lung 
diseases. All smokers included in our study met the criteria 
of ATS for asthma (12). Most of the smokers were also 
under 40 years old (n=14 in the IG and n=8 in the CG). 
The improvements in lung functions and airways hyper- 
responsiveness corroborated that these smokers were real 
asthmatics. No significant difference between the results of 
smokers and non-smokers. 
Apart from FEV,, airway responsiveness continued 
improving in the IG throughout the follow-up. 29% of 
tested IG patients returned to the normal level of PD,, 
1.6 mg or more, compared with 10% in the CG patients. 
Essen-Zandvliet et al. found that 13% returned to normal 
value in a 22-month follow-up study of children (n=58) 
treated with 0.6 mg budesonide (22). Because of the absence 
of long-term follow-up studies among mild asthmatics the 
practical implications of the achieved improvement in 
clinical outcomes for later morbidity and medication 
arrangements are unclear. 
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When compliance was measured by PEF-based self- 
management the groups did not differ from each other. The 
compliance was only dependent on the age of the patients. 
The compliers did not differ from non-compliers in the use 
of medication. 
One important finding was that the intervention indi- 
cated a positive effect on the need for sickness days. The 
risk ratio for sickness days was significantly less in the IG 
than in the CG. Although the improvement in FEV, and 
PEF was significantly greater among IG patients, no corre- 
lation could be found between these and sickness days. 
However, the compliers in both groups had less risk of 
sickness days. Therefore, not only intervention but also the 
use of the PEF meter for follow-up influenced the risk of 
sickness days. Our advice to patients was to use the PEF 
meter during symptomless periods at least once a month 
for objective monitoring of their asthma condition after 
the first treatment year. We also advised the patients to 
perform the PEF monitoring twice a day for 2 weeks before 
the follow-up visits. Most of the patients perceived that as 
too long a time and only 12 patients from both groups 
folllowed the advice. There have been many studies con- 
cerning the benefit of using a PEF meter vs. symtoms 
only in self-management plans, and the results have been 
contradictory (13,23). 
Our study started before the self-management 
programme was recommended in Finland (1) but was 
essentially the same as that adopted nationally except that 
we did not give any rescue corticosteroid tablets to new 
asthmatic patients because that was not our clinical routine. 
On the other hand, we wanted to make sure that all 
exacerbations which were not treated by adjustment 
of inhaled anti-inflammatory medication would be 
recorded. 
During the follow-up it was noticed that the patients 
could not verify exactly how often they had adjusted their 
inhaled anti-inflammatory medication. According to verbal 
information given by the patients there was no difference in 
the amount of drugs used during the first year. After that 
the costs of regular asthma drugs did not differ significantly 
between the groups, although they were slightly lower in 
the IG. 
Most of our patients, even in the IG, preferred symptom- 
based self-management after 1 year in spite of the intensive 
education for PEF-based follow-up. They estimated their 
need for anti-inflammatory drugs according to their use of 
bronchodilators: the reversal in the improved FEV, after 1 
year may mean that they underestimated the need for 
drugs. This finding emphasizes the opinion about the 
importance of PEF-based self-management. The CG used 
more extra primary health-care services and courses of 
antibiotics between 1 and 3 years than the IG. This may 
suggest that asthma exacerbations are still partly treated 
as respiratory infections. They used more extra steroids, 
but the difference was not significant. This may also 
be indicative of inadequate self-management ability in 
the CG. 
HRQOL was measured at baseline and at the 3-year 
control visit. When measured in this way the groups did not 
differ in terms of the generic 15D score or disease-specific 
SGRQ total, symptom, activity or impact scores. An earlier 
analysis of the outcome variables covered by the 15D and 
SGRQ indicated that HRQOL scores may measure factors 
largely unrelated to lung functions, but airway hyper- 
responsiveness may have an influence on the personal 
assessment of HRQOL (24). It is worth noting that the 
HRQOL measures do not cover the behaviour of the 
patients during asthma attacks or in terms of preventing 
attacks. 
Bartter and Pratter reviewed studies of the effects of 
expert-based vs. generalist systems on outcomes in severe 
asthmatics (25). Expert involvement had a positive impact 
on outcomes and overall cost. Our findings in mild 
asthmatics are in agreement with this. To our knowledge, 
this is the first long-term economic evaluation (3-year 
follow-up) among new asthmatics without trial medication 
in routine clinical settings and with outcomes measured 
both by clinical and HRQOL indices. 
Our conclusion, in an incremental cost-effectiveness 
framework, is that if outcome is measured by FEV,, PEF, 
improvement in PDr5 and the need for sickness days, there 
is some support for deciding in favour of intensive patient 
education and supervision for self-management during the 
first treatment year; it produces a better outcome and is at 
least not more expensive than the conventional programme 
after 3-year follow-up. If outcome is measured in terms of 
other lung functions and HRQOL, the programmes are 
statistically not significant with regard to cost and effects, 
implying a similar outcome at a similar cost. However, 
there was a consistent tendency for the intensive pro- 
gramme to be less expensive, but considering the great 
variance in costs the sample sizes were not big enough to 
make the cost difference statistically significant. 
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